AstraZeneca PLC announced Monday that it has received approval from the U.S. Food and Drug Administration (FDA) for a new form of its popular Seroquel schizophrenia treatment, making it the first medicine to treat both the manic and depressive sides of bipolar disorder.
Seroquel, launched in 1997, is one of AstraZeneca's top-selling drugs, with total sales of $2.8 billion last year. The drug is already used to treat acute manic episodes associated with bipolar disorder and schizophrenia, but the FDA approval adds the treatment of patients with depressive episodes
